More Than Skin Deep: A new partnership to ease the hidden burden of Eczema in the UAE
In response to this growing healthcare challenge, Jamjoom Pharma and the Emirates Dermatology Society (EDS) have signed today a Memorandum of Understanding (MoU) to launch ' ECZPLORE' —a pioneering awareness campaign aimed at changing the way eczema is understood, managed, and supported in the UAE.
'Eczema is not just a rash—it's a chronic disease that affects the entire family,' said Dr. Ayman Al Naeem, President of the Emirates Dermatology Society. 'We believe that early education and empathetic support can change the daily reality for children living with eczema. Recent studies suggest that 1 in 5 children in the UAE suffer from eczema, with over half of moderate-to-severe cases remaining uncontrolled. The condition not only disrupts sleep and school life, but also doubles the likelihood of anxiety and depression in caregivers, highlighting the urgent need for broader public awareness.'
The ECZPLORE program will roll out nationwide through schools, clinics, and digital channels. It includes child-friendly materials like coloring books and storybooks, adult-focused guides and magazines, and tailored support for healthcare professionals —all designed to help families better understand the condition and how to lead an 'eczema-friendly' life.
'At Jamjoom Pharma, our purpose is to serve patient well-being through knowledge, care, and community support,' said Dr. Samer Lezzaiq, General Manager - Gulf, Levant & Export Markets at Jamjoom Pharma. 'Through ECZPLORE, we aim to break the silence around eczema, equip caregivers with real tools, and give children the confidence to live without shame.'
The partnership also extends into fungal infection awareness, targeting both patients and professionals with actionable educational campaigns.
Together, Jamjoom Pharma and EDS hope to drive a cultural shift in how chronic skin conditions are perceived and managed, transforming frustration into understanding—and silence into support.
About Jamjoom Pharmaceuticals:
Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system.
With a strong focus on research, innovation, and patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition to expand globally, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine).
Through its state-of-the-art facilities across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.
Jamjoom Pharma Media Contact:
Vivian Fikry, Corporate Communications Director
M: +201222701256
E: Vivian.fikry@jamjoompharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
an hour ago
- Zawya
Madagascar Shows Commitment to Improving Cancer Care, with Focus on Women's Health
An international review has found that Madagascar has laid strong foundations for cancer control, expanding cervical cancer services, maintaining a health workforce and ensuring collaboration between health and radiation safety authorities. The joint imPACT review by the IAEA, World Health Organization (WHO) and International Agency for Research on Cancer (IARC, highlighted the need to further develop oncology professionals and mobilize resources to increase access to cancer care across the country. Cancer claims more than 14 000 lives in Madagascar every year, with women more affected than men with 8 000 deaths. The country registers over 20,000 new cancer cases annually, according to 2022 IARC estimates. Incidence rates are expected to rise with increasing risk factors and an aging population. In June 2025, a team of 13 international experts nominated by the three organizations visited the main healthcare and specialized facilities in the country to conduct the imPACT review – which provides a baseline assessment of services to support Madagascar as the country develops its first comprehensive national cancer governance document. The experts held discussions with national and local health authorities, medical professionals and other stakeholders, and presented preliminary findings to the Minister of Health. 'The Malagasy government is committed to improving cancer care in the country,' Minister of Health Randriamanantany Zely Arivelo said. 'This imPACT assessment is very timely, as we will use its findings to finalize our country's first national cancer control plan.' Focus on Women's Cancers The most common cancer among women in Madagascar is cervical cancer, with a mortality rate of 30 per cent, followed by breast and colorectal cancers. In men, prostate, liver cancer and non-Hodgkin lymphoma are the most common cancers, driven by infectious diseases. The team assessed all elements that can impact cancer care in the country. These include factors such as governance, resources and regulatory frameworks for radiation safety, and components such as surveillance, referral networks, early diagnostic capacities, oncology workforce development opportunities, and readiness for advanced and expanded radiotherapy services. 'The strength of the imPACT review lies in its analysis of the entire cancer continuum,' said Laurent Musango, WHO Representative in Madagascar. 'The assessment reveals a solid foundation for integrating cancer control at the community level, and the potential for an overall strengthening of health systems in terms of prevention and early diagnosis.' The review found that Madagascar has been steadfast in boosting cancer services since a previous assessment in 2015. The country has expanded cervical cancer prevention, with pre-cancerous lesion screening already available and HPV vaccination set to start in October and has undertaken important efforts to modernize and distribute imaging services. The national health system also has an established and overall qualified health workforce, with six faculties of medicine available to train specialized health professionals – particularly in surgery, a critical aspect in cancer treatment. Boosting Capacity for Cancer Care The team recommended that Madagascar continue building capacity to increase and retain human resources in oncology professionals. It also urged further strengthening of radiation safety in medicine and long-term maintenance of existing equipment in nuclear medicine and radiotherapy centres. 'Radiation safety for the protection of patients, public and staff is foundational to providing comprehensive cancer diagnosis and treatment,' said Vasiliki Kamenopoulou, a radiation safety specialist at the IAEA who participated in the imPACT review. 'The Malagasy government is encouraged to reinforce the legal and regulatory framework for safety and bring it in line with the IAEA safety standards.' The review noted that Madagascar should also reinforce prevention and early detection actions for other priority cancers, including working with communities for greater breast cancer awareness and boosting pathology services with additional laboratory staff, equipment and supplies. Partnerships to Expand Services Looking forward, the imPACT review recommended strategies to support Madagascar mobilize resources for cancer control, such as the development of bankable documents to facilitate loans and public-private sector partnerships. The IAEA's Programme of Action for Cancer Therapy and Rays of Hope initiative support countries in bridging gaps in cancer care through partnerships with donors, the private sector and financial institutions. Through its technical cooperation and human health programmes, the IAEA also supports countries in strengthening the quality of nuclear and radiation medicine by providing capacity building, provision of equipment, technical advice and advisory services. Distributed by APO Group on behalf of International Atomic Energy Agency (IAEA).
Arabian Business
5 hours ago
- Arabian Business
Abu Dhabi launches newborn genetic screening programme to detect 815 childhood conditions
The Department of Health – Abu Dhabi (DoH) has launched the Newborn Genetic Screening Programme, one of the most comprehensive of its kind globally, offering whole genome sequencing to screen for more than 815 treatable childhood genetic conditions. The initiative, launched in alignment with the Emirati Genome Council's vision for personalised and precision healthcare, marks a step towards genomics-driven medicine in the UAE. It enables early detection, tailored interventions, and improved health outcomes for newborns. In its first phase, the programme has been introduced at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42, as a voluntary option. It is set to expand across all maternity hospitals in the emirate to cover UAE nationals and children of Emirati mothers. By testing cord blood samples at birth with parental consent, the programme screens for metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy, which can be treated with gene therapy. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Healthcare begins long before symptoms appear, and today, empowered by science and technology, we can act earlier than ever before. This programme reflects Abu Dhabi's commitment to leveraging innovation to serve our community, starting from the first days of life. Through early detection, personalised care, and strategic foresight, we are building a future of healthier generations and reinforcing Abu Dhabi's position as a global leader in proactive, precision healthcare.' Dr. Mohamed Al Ameri, Acting Director of Genome and Biobank Division, Department of Health – Abu Dhabi, said: 'As we work to integrate genomics into our preventative healthcare infrastructure, we aim to expand this initiative to all maternity hospitals in the emirate, demonstrating how genomics can reshape healthcare, shifting from a one-size-fits-all model to a precise, proactive, and personalised approach that improves patient outcomes.' To support the rollout, DoH held workshops with stakeholders to review the gene panel and patient journey, and trained 16 paediatricians and neonatologists on genetic counselling practices. Results are reported within 21 days, with genetic counselling and referrals provided if actionable findings are identified. The Newborn Genetic Screening Programme builds on initiatives under the Emirati Genome Programme, including premarital screening, and is part of a broader strategy to integrate genomics into family health to reduce the prevalence of genetic diseases and support informed decision-making.
Economy ME
8 hours ago
- Economy ME
Jordan sees record growth in medical tourism with over 92,000 visitors by May 2025
Jordan is solidifying its status as the Middle East and North Africa (MENA) region's leading medical tourism destination, recording a remarkable rise in patient arrivals seeking both advanced medical care and natural therapeutic treatments. During the first seven months of 2025, the country witnessed a record increase in medical tourist arrivals, building on steady growth over the past three years. In 2024, over 224,000 medical tourists visited Jordan — up from 202,592 in 2023 and 191,532 in 2022 — demonstrating consistent upward momentum. The growth is powered by two major factors: An expanding range of specialized healthcare services, supported by a highly skilled medical workforce, and the country's natural healing environments like the Dead Sea and Ma'in Hot Springs. Jordan has an expanding range of specialized healthcare services, supported by a highly skilled medical workforce Read: UAE leads in accredited healthcare facilities globally, allocates $1.57 billion for 2025 services A booming global industry Jordan's growth in medical tourism comes amid a global surge in demand for cross-border healthcare . The global medical tourism market, valued at $31.23 – 41.79 billion in 2024, is projected to reach over $160 billion by 2032. The MENA region, particularly GCC countries, has traditionally been a major source of outbound medical travelers. Kuwait sends around 650 patients per month abroad, incurring $1 billion annually, while Saudi Arabia's Health Ministry reported 2,400 patients treated overseas, costing $800 million. Jordan's ability to attract these outbound patients has transformed the country into a regional hub for inbound medical tourism, generating over $1 billion in annual revenue, which contributes approximately 4 percent to Jordan's GDP. 'Our medical tourism sector has a legacy that dates back to the 1970s, when Jordan emerged as one of the top destinations for medical care in the region. The sector is continuing to demonstrate exceptional growth as a preferred therapeutic destination both regionally and globally,' said Dr. Abdelrazzak Arabiyat, managing director of the Jordan Tourism Board. 'The growth in medical tourism is primarily driven by the world-class healthcare services that our hospitals offer, the popularity of the natural therapeutic sites and the renowned hospitality of our country. 'What sets the country's medical tourism sector apart are the cost-effective yet high quality care assured within the country and the diverse natural attractions that add to the well-being of the patients and those who accompany them,' Dr. Arabiyat added. Record-breaking visitor numbers in 2025 In just the first quarter of 2025, Jordan welcomed 51,448 medical tourists, which rose to 92,776 by the end of May, marking a 16.5 percent increase compared to the same period last year. The country is on track to surpass previous records and set a new benchmark for its healthcare tourism sector. Jordan continues to attract patients primarily from Iraq, Saudi Arabia, Palestine, Syria, Yemen, Libya, and other GCC countries, drawn by the nation's quality healthcare, affordability, and cultural proximity. Jordan's growth in medical tourism comes amid a global surge in demand for cross-border healthcare World-class healthcare at competitive prices Jordan's medical care offers substantial cost advantages. Treatments are estimated to be 25 percent to 40 percent cheaper than in the US and Europe, and 5 percent to 10 percent lower than in medical tourism leaders like India, Singapore, and Thailand. The country boasts over 120 hospitals and medical centers, including 71 private and 47 public institutions. Many of these are internationally accredited by bodies such as the Joint Commission International (JCI) and the Health Care Accreditation Council (HCAC), assuring high standards of care and patient safety. Advanced medical capabilities and historic milestones Jordan has been a medical pioneer in the region, performing the first open-heart surgery in 1970 and the first kidney transplant in 1972. The King Hussein Cancer Center (KHCC) remains one of the region's most advanced oncology institutions, completing 250 bone marrow transplants in 2022 with a success rate of over 85 percent, matching international benchmarks. Top hospitals attracting medical tourists include: Jordan Hospital Specialty Hospital Abdali Hospital Al-Kindi Hospital Ibn Al-Haytham Hospital Arab Medical Center King Hussein Cancer Center In the public sector, leading institutions include Royal Medical Services (Medical City) and Al-Bashir Hospital. The country's medical workforce exceeds 30,000 professionals, many of whom are Western-educated and board-certified, offering services in specialties like cardiology, oncology, orthopedics, and fertility. Short waiting times and the widespread use of English among medical professionals further enhance patient confidence and comfort. Natural therapeutic destinations Complementing Jordan's medical infrastructure are unique natural healing sites that support patient recovery: Dead Sea: The lowest point on Earth (400 meters below sea level), offering mineral-rich waters with 33 percent salt content known for treating skin, joint, and respiratory conditions. Ma'in Hot Springs: Featuring thermal waterfalls up to 60°C, known for benefits in treating skin disorders, arthritis, and circulatory issues. These natural resources offer a distinctive recovery experience that combines modern medicine with ancient therapeutic traditions. What sets Jordan's medical tourism sector apart are the cost-effective yet high quality care Strong economic contribution Medical tourism is a significant pillar of Jordan's economy, not only generating over $1 billion annually but also creating thousands of jobs and supporting related sectors such as hospitality, transport, and translation services. Medical tourists are estimated to spend 3 to 5 times more than leisure travelers due to longer stays and broader service needs. Jordan's well-developed hospitality infrastructure, with accommodation options, patient transport, and multilingual support, ensures a smooth experience for international patients and their companions. 'The diversity of medical specialties available in Jordan, combined with our natural therapeutic destinations and skilled healthcare professionals, has created a strong and sustainable medical tourism ecosystem,' Dr Arabiyat said. 'Over the years, we have been focused on promoting our strengths in medical tourism through targeted digital ad campaigns, promotional videos and FAM trips for media and medical delegations, all contributing to the popularity of the country for world-class medical care.' As demand for global healthcare options grows, Jordan is well-positioned to lead the MENA region in offering high-quality, affordable, and holistic medical care. Backed by robust infrastructure, medical expertise, and natural therapeutic advantages, the country continues to elevate its reputation as a premier global medical tourism destination.
